AdaptHealth (AHCO) Scheduled to Post Quarterly Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. AdaptHealth has set its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

AdaptHealth (NASDAQ:AHCO) last released its quarterly earnings data on Tuesday, February 27th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. The business had revenue of $858.23 million for the quarter, compared to the consensus estimate of $825.94 million. On average, analysts expect AdaptHealth to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

AdaptHealth Trading Down 0.9 %

AHCO stock opened at $10.26 on Monday. The firm has a fifty day moving average price of $10.32 and a 200 day moving average price of $8.54. AdaptHealth has a fifty-two week low of $6.37 and a fifty-two week high of $15.37. The firm has a market cap of $1.36 billion, a PE ratio of -1.93, a price-to-earnings-growth ratio of 0.67 and a beta of 1.06. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.00 and a current ratio of 1.21.

Insider Activity at AdaptHealth

In other news, major shareholder James E. Flynn sold 182,607 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the sale, the insider now directly owns 11,643,769 shares of the company’s stock, valued at approximately $128,314,334.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder James E. Flynn sold 182,607 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the sale, the insider now directly owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder James E. Flynn sold 52,487 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $10.93, for a total transaction of $573,682.91. Following the transaction, the insider now owns 11,826,376 shares of the company’s stock, valued at approximately $129,262,289.68. The disclosure for this sale can be found here. 13.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on AHCO. UBS Group increased their price target on AdaptHealth from $9.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Jefferies Financial Group downgraded shares of AdaptHealth from a “buy” rating to a “hold” rating and cut their price target for the company from $14.50 to $8.00 in a report on Monday, January 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $13.00 price objective on shares of AdaptHealth in a research note on Monday, March 4th. Finally, Truist Financial upped their target price on AdaptHealth from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $12.10.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.